Mexiletine

Mexiletine

Mexiletine
Systematic (IUPAC) name
(RS)-1-(2,6-dimethylphenoxy)propan-2-amine
OR
2-(2-aminopropoxy)-1,3-dimethylbenzene
Clinical data
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • AU: B1
  • US: C (Risk not ruled out)
Legal status
Routes of
administration
Oral, IV
Pharmacokinetic data
Bioavailability 90%
Protein binding 50-60%
Metabolism Hepatic (CYP2D6 and 1A2- mediated)
Biological half-life 10-12 hours
Excretion Renal (10%)
Identifiers
CAS Registry Number  Y
ATC code C01
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  Y
ChEMBL  Y
Chemical data
Formula C11H17NO
Molecular mass 179.259 g/mol
 Y   

Mexiletine (INN) (sold under the trade name Mexitil) is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines.[1] It is used to treat arrhythmias within the heart, or seriously irregular heartbeats. It slows conduction in the heart and makes the heart tissue less sensitive. Dizziness, heartburn, nausea, nervousness, trembling, unsteadiness are common side effects. It is available in injection and capsule form.

Class IB antiarrhythmics decrease action potential frequency by lengthening the repolarization phase. This is achieved by blocking sodium channels.[2]

This drug is now no longer freely available as a licensed product in either the US or the UK. It can be imported to the UK as an unlicensed, 'named-patient' drug. Its use in arrhythmias is restricted to use in life-threatening conditions only.

Mexiletine may also be of use in patients experiencing refractory pain[3] and is also effective for treating muscle stiffness resulting from myotonic dystrophy (Steinert's disease) or nondystrophic myotonias such as myotonia congenita (Thomsen disease).

Contents

  • Synthesis 1
  • References 2
  • Further reading 3
  • External links 4

Synthesis

Mexiletine synthesis:[4][5][6][7]

References

  1. ^ Sergio Canavero; Vincenzo Bonicalzi (13 October 2011). Central Pain Syndrome: Pathophysiology, Diagnosis and Management. Cambridge University Press. pp. 286–.  
  2. ^ Mexiletine, RxList.com
  3. ^ Sweetman S (ed.) (2002).  
  4. ^ H. Koppe, W. Kummer, U.S. Patent 3,954,872 (1976).
  5. ^ H. Koppe, W. Kummer, U.S. Patent 3,659,019 (1972).
  6. ^ C.H. Boehringer Sohns, Fr 1551055  (1968).
  7. ^ H. Koppe, W. Kummer, U.S. Patent 4,031,244 (1977).

Further reading

  • Peck T; Hill S, Williams M (eds.) (2004). Pharmacology for Anaesthesia and Intensive Care (2nd ed.).  

External links

  • MedlinePlus Drug Information: Mexiletine